156 related articles for article (PubMed ID: 17486696)
1. Not all c-kit mutations can be corrected by imatinib.
Lasota J
Lab Invest; 2007 Apr; 87(4):317. PubMed ID: 17486696
[No Abstract] [Full Text] [Related]
2. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
Nakagomi N; Hirota S
Lab Invest; 2007 Apr; 87(4):365-71. PubMed ID: 17259998
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.
Isotani M; Yamada O; Lachowicz JL; Tamura K; Yagihara H; Fujino Y; Ono K; Washizu T; Bonkobara M
Br J Haematol; 2010 Jan; 148(1):144-53. PubMed ID: 19804453
[TBL] [Abstract][Full Text] [Related]
4. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
5. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.
Kobayashi M; Sugisaki O; Ishii N; Yamada O; Ito K; Kuroki S; Sasaki Y; Ono K; Washizu T; Bonkobara M
Vet J; 2012 Jul; 193(1):264-7. PubMed ID: 22153896
[TBL] [Abstract][Full Text] [Related]
6. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
[TBL] [Abstract][Full Text] [Related]
7. Systemic mastocytosis: current classification and novel therapeutic options.
Barbie DA; Deangelo DJ
Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
[TBL] [Abstract][Full Text] [Related]
8. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade.
Beghini A; Bellini M; Magnani I; Colapietro P; Cairoli R; Morra E; Larizza L
Exp Hematol; 2005 Jun; 33(6):682-8. PubMed ID: 15911092
[TBL] [Abstract][Full Text] [Related]
9. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
Zhang LY; Smith ML; Schultheis B; Fitzgibbon J; Lister TA; Melo JV; Cross NC; Cavenagh JD
Leuk Res; 2006 Apr; 30(4):373-8. PubMed ID: 16183119
[TBL] [Abstract][Full Text] [Related]
10. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.
Merante S; Chichino G; Boveri E; Gottardi E; Soverini S; Cilloni D; Martinelli G
J Clin Oncol; 2006 Feb; 24(4):e6-7. PubMed ID: 16446324
[No Abstract] [Full Text] [Related]
11. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis.
Musto P; Falcone A; Sanpaolo G; Bodenizza C; Carella AM
Leuk Res; 2004 Apr; 28(4):421-2. PubMed ID: 15109544
[No Abstract] [Full Text] [Related]
12. Imatinib in melanoma: a selective treatment option based on KIT mutation status?
Becker JC; Bröcker EB; Schadendorf D; Ugurel S
J Clin Oncol; 2007 Mar; 25(7):e9. PubMed ID: 17327598
[No Abstract] [Full Text] [Related]
13. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
[No Abstract] [Full Text] [Related]
14. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
15. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
16. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Bauer S; Duensing A; Demetri GD; Fletcher JA
Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
[TBL] [Abstract][Full Text] [Related]
17. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation.
Wakai T; Kanda T; Hirota S; Ohashi A; Shirai Y; Hatakeyama K
Br J Cancer; 2004 Jun; 90(11):2059-61. PubMed ID: 15150562
[TBL] [Abstract][Full Text] [Related]
18. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
[TBL] [Abstract][Full Text] [Related]
19. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
[TBL] [Abstract][Full Text] [Related]
20. Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
Tamborini E; Negri T; Miselli F; Lagonigro MS; Pricl S; Pilotti S
J Natl Cancer Inst; 2006 Nov; 98(21):1583-4. PubMed ID: 17077361
[No Abstract] [Full Text] [Related]
[Next] [New Search]
